A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Condition: Cancer
MeSH terms: Melanoma
Intervention: GSK2118436; Dacarbazine (DTIC)
Intervention description: 150 mg twice daily; Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
Intervention MeSH terms: Dacarbazine; Dabrafenib
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 251.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Metastatic melanoma; melanoma; BRAF mutant; Advanced melanoma

Summary:

      BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and
      tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced
      (Stage III) or metastatic (Stage IV) melanoma. Subjects will be randomized to receive 150 mg
      of GSK2118436 twice daily or 1000 mg/m2 DTIC every 3 weeks and continue on treatment until
      disease progression, death, or unacceptable adverse event. Subjects who progress on DTIC will
      be allowed to crossover to an optional extension arm of the study to receive GSK2118436.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Adults at least 18 years of age

          -  Has advanced (unresectable Stage III) or metastatic (Stage IV) melanoma that is BRAF
             mutation positive (V600E)

          -  Is treatment naive for advanced (unresectable) or metastatic melanoma, with the
             exception of Interleukin 2 (IL-2) which is allowed.

          -  Has measurable disease according to RECIST 1.1 criteria.

          -  Women of child-bearing potential must have a negative pregnancy test within 14 days
             prior to the first dose of study treatment.

          -  Women with reproductive potential must be willing to practice acceptable methods of
             birth control during the study and for up to 4 weeks after the last dose of study
             medication.

          -  Men with reproductive potential must be willing to practice acceptable methods of
             birth control during the study and for up to 16 weeks after the last dose of study
             medication.

          -  Must have adequate organ function.

          -  Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

        Exclusion Criteria:

          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy,
             biologic therapy or surgery).

          -  Evidence of active central nervous system (CNS) disease.

          -  Previous treatment for metastatic melanoma, including treatment with BRAF or MEK
             inhibitor.

          -  A history of other malignancy. Subjects who have been disease-free for 5 years or
             subjects with a history of complete resected non-melanoma skin cancer or successfully
             treated in situ carcinoma are eligible.

          -  History of Human Immunodeficiency Virus (HIV) infection.

          -  Certain cardiac abnormalities